Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Influenza virus trivalent vaccine - GlaxoSmithKline

Drug Profile

Influenza virus trivalent vaccine - GlaxoSmithKline

Alternative Names: alpha-Rix; Fluarix; Fluarix Trivalent; Fluarix-VB; Inactivated influenza vaccine - GlaxoSmithKline; Influsplit SSW

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 01 Jul 2013 GlaxoSmithKline plans a phase III trial for Influenza virus infections (prevention) in Germany (NCT01884519)
  • 18 Jul 2011 US FDA approves Fluarix® for the 2011-2012 influenza season in USA
  • 31 Jul 2010 US FDA approves Fluarix® for the 2010-2011 influenza season in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top